Dermata Therapeutics (DRMA) Change in Accured Expenses (2020 - 2026)

Dermata Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$445640.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 410.14% year-over-year to -$445640.0; the TTM figure through Mar 2026 stood at -$574477.0 (down 175.66% YoY), while the FY2025 annual figure was $14852.0, down 96.35% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$445640.0, down from $521754.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $521754.0 in Q4 2025, with the low at -$695894.0 in Q2 2025.
• The 5-year median for Change in Accured Expenses is $134421.0 (2024), against an average of $3005.3.
• Peak annual rise in Change in Accured Expenses reached 288.15% in 2025, while the deepest fall reached 10919.25% in 2025.
• Dermata Therapeutics' Change in Accured Expenses stood at -$594650.0 in 2022, then soared by 153.01% to $315229.0 in 2023, then plunged by 57.36% to $134421.0 in 2024, then soared by 288.15% to $521754.0 in 2025, then tumbled by 185.41% to -$445640.0 in 2026.
• Business Quant data shows DRMA's Change in Accured Expenses at -$445640.0 in Q1 2026, $521754.0 in Q4 2025, and $45303.0 in Q3 2025.